PLSE - Company ID 0001625101
The table below shows Pulse Biosciences, Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$54.12M | -$36.34M | -$33.04M | -$47.01M | -$54.10M | -$35.37M |
| Capital expenditure | $315.00K | $125.00K | $121.00K | $401.00K | $437.00K | $441.00K |
| Investing cash flow | -$335.00K | -$125.00K | -$121.00K | -$401.00K | $7.56M | $10.04M |
| Dividends paid | - | - | - | - |
Pulse Biosciences, Inc. reported operating cash flow of -$54.12M for fiscal year 2025. That is down 48.9% from -$36.34M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow declined from -$8.05M (FY 2016) to -$54.12M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $17.15M | $110.14M | $16.39M | $79.94M | $62.69M | $30.89M |